Galena Biopharma (GALE) Misses Q2 EPS by 8c

Galena Biopharma (NASDAQ: GALE) reported Q2 EPS of ($0.17), $0.08 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $2.99 million.

For earnings history and earnings-related data on Galena Biopharma (GALE) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Helius Medical Technologies (HSDT) Misses Q2 EPS by 31c
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c